Oscotec’s FDA-approved clinical trials for treatment of acute myeloid leukemia

Oscotec(CEO Jung-Geun Kim), a new drug development company, announced on the 13^th that it made an agreement since the U.S. Phase 1 clinical trial project of the next-generation new drug candidate(SKI-G-801) for the treatment of acute myeloid leukemia(AML) was selected as the non-clinical/clinical support project based on the Ministry of Health and Welfare health and medical development plan.

T...